
|Articles|October 12, 2019
Prescriber's Guide to Lasmiditan
In October 2019, the FDA approved Eli Lilly's lasmiditan, marketed as Reyvow, for the acute treatment of migraine with or without aura in adults. The drug is the first approved from a new class of serotonin (5-HT)1F receptor agonists. This downloadable PDF serves as a convenient, consolidated prescribing guide to help you incorporate this new migraine therapy into your clinical practice.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
4
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
5

















